Tecotabart vedotin

N/A

Report date: 2026/03/04 20:01:44

Base Information

Drug NameTecotabart vedotin
Drug Alias NameLM-302TPX-4589BMS-986476
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-CLDN18Tubulin inhibitorsTubulin polymerisation inhibitors
TargetsClaudin-18 splice variant 2Tubulin
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursPancreatic Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesLaNova Medicines Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Chia Tai Tianqing Pharmaceutical Technology Development Co LtdShanghai Zhongshan HospitalTurning Point Therapeutics Inc +[5] 
Inactive CompaniesN/A
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursPancreatic Neoplasms +[8] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A